Maculaser Ltd

Fantastic few days at the premium LSI Europe '24 #MedTech event in sunny Portugal! Our CEO Jani Tirronen had the opportunity to present #Maculaser to investors and engage with leading clinical and regulatory experts from both sides of the Atlantic. The highlight, as always, was exchanging ideas with peer innovators, including the amazing team at Askel Healthcare Ltd from Finland. Next up tomorrow: European Society of Retina Specialists (EURETINA) '24 meeting in Barcelona! #funding #ophthalmology #retina

As we continue on the #RoadToEurope we’re showcasing global innovation from the innovators selected to present in Portugal this September. Today we’re showcasing 3 Innovators in Finland selected to present at #LSIEurope24: 1. Virpi Muhonen — Askel Healthcare Ltd → Seeking to transform surgical knee cartilage treatment and recovery. The company's COPLA implant is intended for the repair of full-thickness cartilage and bone-cartilage lesions in the knees of adult patients. The implant is a biodegradable polymer scaffold that allows for immediate full weight-bearing post-surgery. 2. Jani Tirronen — Maculaser Ltd → Develops novel technologies for the treatment of common retinal diseases, including age-related macular degeneration (AMD). At the core of the company's laser treatment platform is its unique retinal sensor technology that allows the precise control of temperature of the targeted retinal tissue, which is essential to achieve optimal regenerative effects and promote healing without damaging the retina. 3. Pasi Kankaanpää — Biomendex → Develops Adaptos bone graft substitutes for various surgical indications. Adaptos is an adaptable bone graft substitute intended for use throughout the musculoskeletal system. The product combines osteoconductive and osteostimulative ceramic materials with a durable, elastic, and resilient carrier material. Join us this September to meet with these Innovators and hundreds of other global Medtech and Healthtech leaders at LSI Europe ‘24 in Sintra, Portugal.

We are pleased to announce that Aki Vartiainen joins the Maculaser team as Clinical Trial Manager.   Aki brings strong expertise to our team, having worked on over 20 clinical trials, including First-In-Human and post-market studies. With 7 years of experience as a pharmaceutical clinical trial project manager, Aki is well-suited to lead the planning and execution of clinical trials to advance our next-generation ophthalmic products and vision-saving technologies to market.   Welcome to Maculaser, Aki!   #maculaser #ophthalmology #retina #medtech #ClinicalTrials #ProjectManagement #AMD #MacularDegenaration #MacularEdema #ERG https://lnkd.in/d_DBd2BH

Maculaser has been granted a Japanese patent for its method and device for determining changes in retinal and/or brain temperature. This is Maculaser’s first patent outside the EU and US and marks a significant milestone for the company. The newly granted patent, JP 7475071 B2, strengthens the protection of Maculaser’s primary treatment facilitator, retinal temperature control. Currently, Maculaser holds a total of five patent families with granted patents. #retina #patents #maculaser #ophthalmology https://lnkd.in/dE_JBA7P

We are excited to announce that Kirsty Happonen joins the Maculaser team as Head of Regulatory Affairs and Quality Assurance.   Kirsty is a Canadian with 10+ years bringing medical devices to market in industries such as dental, imaging and point-of-care diagnostic devices. She has a background in technical product conformity and compliance. In her RAQA role, Kirsty will be the personal responsible for regulatory compliance, and the QMS and quality assurance contact, who is working to bring our next-generation ophthalmic products and vision-saving technologies to market.   Welcome to Maculaser, Kirsty!   #maculaser #ophthalmology #retina #medtech #RAQA #tomarket #QMS #regulatoryaffairs